Is Nvidia Stock Your Ticket to Becoming a Millionaire? The semiconductor bellwether could make investors richer, given the terrific growth opportunity it is poised to benefit from.
MP Materials Aims to Eliminate America's Dependence on Rare-Earth Imports After 2028 MP Materials' 10X factory will produce 10,000 tons of rare-earth magnets a year. It may need to get even bigger.
New Medicare Rule Has Advocates Concerned About Limits on Care Medicare is imposing strict new restrictions that advocates are worried could affect retirees.
Coinbase Just Delivered Fantastic News to Its Customers. But Is It a Buy? Coinbase's diversification away from crypto should make it less susceptible to the ebbs and flows of the crypto market.
'There Will Be More Casualties,' Warns Pete Hegseth Amid US-Iran War, Former Joint Chiefs Chair Fears Lengthy War US Defense Secretary Hegseth acknowledges rising casualties in Iran conflict. Former Chairman Mullen warns of potential for lengthy war.
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken private by Kuva Labs for $5.00 per share + $1.00 CVR.
Elon Musk Fires Back At AOC After 'Billionaire Conman' Remark, Jokes He's A 'Trillionaire' Elon Musk fired back at Alexandria Ocasio-Cortez's "billionaire conman" comment with a joking "*trillionaire" reply.
Stablecoin Market Cap Hits Record $313 Billion Amid US-Iran War, Crypto Winter The total stablecoin market capitalization reached a record $313 billion, rising 1.14% over the past week, according to DefiLlama data.
Starfighters Space Drops 5% Overnight As Fuel Cost Fears Offset Defense Demand Amid US-Iran War Starfighters Space (FJET) drops 5% overnight as rising jet fuel prices and geopolitical tension weigh on the post-IPO rally.
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews The founder cited remarks from a former FDA official and an NIH Director supporting mechanism-based review to speed patient access to therapies like Anktiva.
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout The CEO said Sellas is pursuing a “security force” immunotherapy strategy that trains immune cells to recognize cancer even as tumors evolve.
